Reflow Medical, Inc. announced that the FDA has granted de novo clearance for the company’s Spur peripheral retrievable stent ...

Hyporesponsiveness to erythropoiesis-stimulating agents (ESAs), whether defined as lack of hemoglobin response to typical ESA doses or need for higher ESA doses to reach hemoglobi ...

The rise of GLP-1 agonist therapies has transformed obesity treatment, delivering unprecedented results and revealing their ...

Even if VNS does have real benefits, it’s not a cure for these conditions, he says, and it should be used alongside standard medical care. “These devices ... not seeing any adverse effects ...

Challenges associated with studying CLTI, pros and cons of common endpoints, hurdles in study design, and recommendations for ...

The ultrasound catheter is being tested in the PreVail-PH2 study, an early feasibility trial enrolling PH patients with left ...

Ten electronic databases were searched (all conducted by RNK): MEDLINE, EMBASE, International Pharmaceutical Abstracts, Cumulative Index to Nursing and Allied Health Literature, Scopus, Health ...

The trial met the primary safety endpoint with no device-related major adverse events observed within 48 hours post-procedure. Credit: PeopleImages.com – Yuri A/Shutterstock. Inquis Medical has ...

As the medical device industry transitions to a highly consumer-driven marketplace, incorporating user feedback into new ...

Cyberattackers are well aware of medical device software weaknesses. Are you? RunSafe Security CEO Joe Saunders offers ...